Czechia· CZ-0238222
CABLIVI
A caplacizumab product containing caplacizumab, registered in Czechia by Ablynx NV, Zwijnaarde. The same ATC class is registered in 12 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Caplacizumab is registered in 12 of 19 countries.
Countries holding a registration under ATC B01AX07 (caplacizumab), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 8 of them publish a price we can compare per daily dose
Caplacizumab · ATC B01AX07
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of caplacizumab costs, country by country.
Normalised to the WHO defined daily dose (10 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Caplacizumab · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$4847.79
The record
At a glance
SÚKL (Czech Republic)- Active substance
- CAPLACIZUMAB
- Manufacturer
- Ablynx NV, Zwijnaarde
- Country
- Czechia (CZ)
- ATC code
- B01AX07
- ATC class
- Caplacizumab
- Defined daily dose
- 10 mg, P
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
142 interactions on record for caplacizumab.
Graded by severity as the source publishes them — 72 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Caplacizumab · interactions on record
142 records
- 72 severe
- 70 moderate
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- Antithrombin IIIB01AB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Caplacizumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayCabliviAblynx
- FinlandCabliviAblynx NV
- FranceCABLIVI 10 mg, poudre et solvant pour solution injectableABLYNX (BELGIQUE)
- United KingdomCablivi 10mg powder and solvent for solution for injection vialsSanofi
- IrelandCablivi 10 mg Powder and solvent for solution for injectionAblynx
- IcelandCabliviAblynx NV
- Japanカプラシズマブ（遺伝子組換え）サノフィ
- NetherlandsCablivi 10 mg, Poeder en oplosmiddel voor oplossing voor injectieAblynx NV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Cablivi
- Liechtenstein · Cablivi
- Norway · Cablivi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bfd88a36-c55f-4815-b6fa-b914992e0a40 GET /v1/drugs/bfd88a36-c55f-4815-b6fa-b914992e0a40?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INJ PSO LQF",
"source": "sukl",
"strength": "10MG",
"pack_size": "7X(1+1X1ML ISP+AD+J)",
"substance": "CAPLACIZUMAB",
"cz_kod_sukl": "0238222",
"product_type": "BT",
"substance_codes": "19667",
"registration_state": "R",
"registration_number": "EU/1/18/1305/002"
}See everything about caplacizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.